Who are IV Lidocaine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Exparel TAP + multi-modal pain regimen, carbamazepine ER (Equetro), Remifentanil+Lidocaine, Exparel/bupivacaine mixture, intraarticular injection with ropivacaine, Suzetrigine (SUZ).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iv-lidocaine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

IV Lidocaine — Competitive Intelligence Brief

IV Lidocaine (IV Lidocaine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic / Antiarrhythmic agent (Class IB). Area: Anesthesia / Cardiology.

marketed Local anesthetic / Antiarrhythmic agent (Class IB) Voltage-gated sodium channels Anesthesia / Cardiology Small molecule Live · refreshed every 30 min

Target snapshot

IV Lidocaine (IV Lidocaine) — University of Washington. IV lidocaine blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IV Lidocaine TARGET	IV Lidocaine	University of Washington	marketed	Local anesthetic / Antiarrhythmic agent (Class IB)	Voltage-gated sodium channels
Exparel TAP + multi-modal pain regimen	Exparel TAP + multi-modal pain regimen	Pacira Pharmaceuticals, Inc	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
carbamazepine ER (Equetro)	carbamazepine ER (Equetro)	Massachusetts General Hospital	marketed	Anticonvulsant; mood stabilizer	Voltage-gated sodium channels
Remifentanil+Lidocaine	Remifentanil+Lidocaine	The First Affiliated Hospital of Zhengzhou University	marketed	Opioid analgesic + Local anesthetic combination	Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)
Exparel/bupivacaine mixture	Exparel/bupivacaine mixture	Wake Forest University Health Sciences	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
intraarticular injection with ropivacaine	intraarticular injection with ropivacaine	Hvidovre University Hospital	marketed	Local anesthetic	Voltage-gated sodium channels
Suzetrigine (SUZ)	Suzetrigine (SUZ)	Vertex Pharmaceuticals Incorporated	marketed	Selective sodium channel inhibitor	Voltage-gated sodium channels (Nav)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic / Antiarrhythmic agent (Class IB) class)

University of Washington · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IV Lidocaine — Competitive Intelligence Brief. https://druglandscape.com/ci/iv-lidocaine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab